Platelet Additive Solution is a plasma substitute for the preparation and storage of Buffy Coat (BC) and aphaeresis platelet concentrates (PCs)
Platelet additive solution SSP+
Patient safety start with platelet quality.
SSP+ is our lastest generation of Platelet Additive Solution (PAS-E). The use of SSP+ is a major step to improve transfusion safety : reducing adverse transfusion reaction and ABO incompatibility while extending platelet shelf-life.
Macopharma develops and manufactures platelet additive solution that improve platelet quality, patient safety and patient outcome worldwide.
Maintaining platelet quality is essential for the safe and effective transfusion. With SSP+, our innovative solution, platelets retain their morphological consistency and reducing the negative effects of prolonged storage.
Trusted worldwide, more than 20 millions of Platelet concentrates have been stored in SSP+, across more than 40 countries (Data from 2025).
Benefits
Superior Platelet quality :
• More standardised platelet concentrates,
• Improved storage conditions (pH, HSR, Aggregation,…)
Plasma saving & Added Value :
• Recovers additional plasma for alternative uses
• Increases availability of therapeutic plasma
• Generates additional income from recovered plasma
Improve safety :
• Reduction in plasma volume transfused with platelets concentrates• Decrease in adverse transfusion reactions
• Reduction of immunological risks
• Improvement in microbiological safety
Optimized Stock Management :
• Platelet shelf life can be extended up to 7 days (according to the local regulations),
• Availability of platelets is improved over weekends and public holidays,
• The discard-rate can be reduced by decreasing the number of outdated platelet concentrates,
• Platelet concentrates can be stored up to 4 days without agitation.
Features
Different volumes available : 200mL, 220mL, 250mL, 280mL, 300mL, 500mL
2 connection modes available (for both manual & aphaeresis)
Barcode ISBT 128
Polyolefin bag (Non PVC)
Compatible with all techniques (manual and automatic)
Compatible with all pathogen inactivation technologies
NEW
In accordance with MDR (UE) 2017/745 and contains NO-DEHP*
* Some references are not available for sale in all countries. Please contactyour local sales representative or Macopharma to enquire about products’availability in your country
Patient Safety
Macopharma is a major global player in the filtration of blood components, with unique know-howand expertise. We have a deep understanding of your requirements and strive to provide you withreliable and robust filters, guaranteeing high performance stability and reproducibility.
This information is for exclusive use of healthcare professionals.
The products are not available in every country, please contact your sales representative.
MACOPHARMA • Rue Lorthiois 59240 Mouvaux France • Tel : + 33 (0) 3 20 11 84 00 • Fax : +33 (0) 3 20 11 84 03
Société par actions simplifiée au Capital de 493.115 € RCS Lille Metropole 391 600 905 • Code APE 4641 Z • TVA FR 313 916 009 05